Hydroxychloroquine and 4‐phenylbutrrate (4PBA) are under investigation for enhancing cell surface BMPR‐II expression, and Etanercept has shown efficacy in preclinical models of PAH by preventing the loss of cell surface BMPR‐II on PASMCs. The gene discussed is BMPR2; the disease is pulmonary arterial hypertension.